Progress, Potential, and Possibilities Podcast / Show

Ira Pastor
  • 5.0 (6)
  • SCIENCE
  • UPDATED SEMIWEEKLY

Interviews and Discussions With Fascinating People Who are Creating A Better Tomorrow For All Of Us - Host - Ira S. Pastor

  1. 12H AGO

    How AI + Satellites Are Transforming Global Infrastructure Monitoring | Sean Donegan - CEO - Satelytics

    Send us Fan Mail We may be building something entirely new - a kind of digital nervous system for the planet, where satellites and AI are constantly sensing and interpreting what’s happening on Earth. Sean Donegan is the Founder and CEO of Satelytics ( https://www.satelytics.com/ ), a pioneer in applying artificial intelligence to high-resolution satellite imagery to monitor and protect critical infrastructure at global scale. With more than three decades of experience in enterprise software and predictive analytics, Sean has built a career at the intersection of data, automation, and real-world industrial problem solving. Long before “GeoAI” became a buzzword, Sean recognized the potential of combining remote sensing with advanced analytics to deliver continuous, actionable intelligence across vast physical assets - pipelines, power grids, and water systems that were historically difficult to monitor in real time. Under his leadership, Satelytics has helped move satellite-based monitoring from experimental pilot programs into core operational systems, enabling energy and utility companies to detect methane leaks, identify environmental risks, and prevent costly infrastructure failures before they escalate. Sean is a serial entrepreneur who has founded or led four successful software companies. Prior to Satelytics, he spent 15 years as CEO of Westbrook Technologies, where he engineered one of the more dramatic turnarounds in enterprise software - transforming a struggling firm into a profitable global leader serving customers in more than 50 countries. Earlier, he developed predictive analytics platforms for the oil and gas sector through his firm Sean Allen LLC, laying the groundwork for the industrial AI applications he is advancing today. Known for his energetic leadership style and sharp wit, Sean combines deep technical insight with a practical understanding of how large industrial operators adopt new technologies. Today, he is at the forefront of a major shift in how the world’s most critical infrastructure is monitored - where satellites, AI, and falling data costs are converging to make continuous, global surveillance not just possible, but essential. #GeoAI #SatelliteTechnology #ArtificialIntelligence #MethaneDetection #OilAndGas #EnergyInnovation #ClimateTech #RemoteSensing #SpaceTech #Infrastructure #Utilities #EnvironmentalMonitoring #DataAnalytics #PredictiveAnalytics #SmartInfrastructure #WildfirePrevention #TechPodcast #FutureOfAI #IndustrialAI #EarthObservation Support the show

    49 min

  2. 1D AGO

    Prescribing Nature For Human And Planetary Health - Jennie McCaffrey - Vice President of Health & Education - BC Parks Foundation

    Send us Fan Mail Doctors in North America are now prescribing something you can’t buy at a pharmacy… and it’s backed by a growing body of science.  Jennie McCaffrey is the Vice President of Health & Education at the BC Parks Foundation ( https://bcparksfoundation.ca/ ), where she leads initiatives designed to connect people to nearby nature for the benefit of both human health and the planet. With a career spanning environmental education, behavior change, and large-scale community engagement, Jennie has worked across nonprofits, government, and industry to inspire action on biodiversity, climate, and public health. Her work has helped build movements around ambitious conservation goals like 25x25 and 30x30, while also translating those global targets into everyday human behaviors - getting people outside, active, and reconnected with nature. Before stepping into her current role, Jennie led education and engagement efforts at the Invasive Species Council of BC, where she scaled programs dramatically during a period of rapid organizational growth. She has also spent over a decade delivering hands-on environmental education through the Habitat Conservation Trust Foundation and its WildBC program, empowering communities to better understand and protect the natural world. Jennie holds a Master’s in Environmental Education and a Bachelor’s in Conservation Biology from University of British Columbia, and she brings both scientific grounding and deep community experience to her mission: making nature a daily, accessible part of people’s lives - and a cornerstone of healthier societies. #NatureAsMedicine #HealthyByNature #ParkPrescriptions #PaRx #PreventiveHealth #PublicHealthInnovation #MentalHealth #Longevity #BehaviorChange #EnvironmentalHealth #Biodiversity #ClimateAndHealth #OutdoorWellness #NatureTherapy #HealthcareInnovation #FutureOfHealth #PopulationHealth #WellnessStrategy #UrbanNature #HealthOptimization #BiohackingNature #Sustainability #BCParks #HumanPerformance #NatureConnection Support the show

    51 min

  3. 4D AGO

    Bioelectronics & Precision Neuromodulation: The Next Therapeutic Frontier | Dr. Robert Spoelgen, Ph.D. - Vice President and Head of Bioelectronics, Merck KGaA Darmstadt Germany

    Send us Fan Mail Imagine a device that can sense disease in real time… and treat it instantly. That’s the promise of Bioelectronics. Dr. Robert Spoelgen, Ph.D. is Vice President and Head of Bioelectronics at Merck KGaA Darmstadt Germany ( https://www.emdgroup.com/en/the-future-transformation/healing-power-electronics.html ), where he leads one of the company’s most forward-looking initiatives at the intersection of neuroscience, medical devices, and digital health. In this role, he founded and now drives Merck KGaA Darmstadt Germany’s bioelectronics strategy, focused on developing implantable neurostimulation technologies - particularly selective peripheral nerve stimulation platforms - to treat chronic diseases and enable real-time patient monitoring. Dr. Spoelgen’s work reflects a broader shift within pharma toward “beyond the pill” modalities, combining device-based therapies with data-driven insights. His team collaborates with medtech partners to develop precision neuromodulation approaches, including vagus nerve stimulation platforms aimed at conditions ranging from hypertension to inflammatory disease. Before launching bioelectronics at Merck KGaA Darmstadt Germany, Dr. Spoelgen led Technology Foresight & Scouting, where he helped identify and incubate new innovation domains including AI-driven drug discovery, liquid biopsy, neuromorphic systems, and synthetic biology. He was also a co-founder of Merck KGaA Darmstadt Germany’s internal Business Builder unit, designed to create new ventures beyond the company’s traditional portfolio. Earlier in his career, Dr. Spoelgen held executive and R&D leadership roles across biotech and med-tech, including serving as CEO of Anteis S.A. and leading medical device R&D at Merz Pharmaceuticals. His scientific foundation is in molecular neuroscience: he completed his PhD at the Max Delbrück Center and a postdoctoral fellowship at Harvard Medical School under Brad Hyman, focusing on Alzheimer’s disease and neurodegeneration. Dr. Spoelgen's early research - spanning amyloid biology, synaptic signaling, and neurogenesis - resulted in publications in leading journals such as Neuron, PNAS, and Journal of Neuroscience. This deep neuroscience background now informs his efforts to translate neural circuit insights into programmable therapeutic systems. #Bioelectronics #VagusNerve #Neurostimulation #FutureOfMedicine #DigitalHealth #PrecisionMedicine #Neuroscience #MedTech #HealthcareInnovation #Pharma #DrugDiscovery #Neurotechnology #ChronicDisease #Inflammation #AIinHealthcare #ClosedLoopSystems #Electroceuticals #MedicalDevices #Biotech #MerckKGaA Support the show

    35 min

  4. 4D AGO

    Bioprinting The Human Body In Wartime | Ukraine’s Medtech Revolution | Denys Gurak, Founder; Kateryna Osetrova, Executive Director; Michael Pluzhnyk, Chief Technology Officer; biodrook

    Send us Fan Mail In times of crisis, innovation doesn’t slow down - it accelerates. Over the past several years, Ukraine has become globally recognized for its rapid advances in defense technology - particularly in drones and distributed manufacturing. But alongside that transformation, another revolution has been quietly taking shape: the future of medicine, built under extreme conditions. Today, we’re exploring that frontier through the work of biodrook (https://biodrook.com/en) - a company developing 3D-printed, biodegradable bone implants designed to help the body regenerate itself. And joining me are three of the leaders building that vision. Denys Gurak is the Founder of biodrook and a longtime innovator at the intersection of technology, policy, and defense. Through his work at MITS Capital, he’s been deeply involved in scaling Ukraine’s defense-tech ecosystem and connecting it to global supply chains - bringing a systems-level perspective on how innovation happens under pressure. Kateryna Osetrova is Executive Director for Ukraine at biodrook, with a background spanning stem cells, exosome-based therapies, and regenerative medicine. She brings a deep understanding of how these technologies move from concept to clinical reality - and what it takes to deliver them to patients. Michael Pluzhnyk is biodrook’s Chief Technology Officer, and is leading the engineering and production of these next-generation implants - translating cutting-edge materials science and 3D printing into real-world medical devices now being deployed in Ukraine. Together, they represent something rare: the convergence of vision, biology, and engineering - applied not in ideal conditions, but in one of the most challenging environments imaginable. So this is a conversation about more than just medical technology. It’s about rebuilding the human body. It’s about building systems that can operate under extreme stress. And ultimately, it’s about what the future of medicine looks like when innovation is no longer optional - but necessary. biodrook Video - https://youtu.be/sK2Y_-A17MI?si=fliuc8oSgaqWxGIE #biotech #regenerativemedicine #3dprinting #bioprinting #medtech #futureofmedicine #healthcareinnovation #orthopedics #tissueengineering #biodegradable #startups #ukraine #innovation #science #technology #medicalbreakthrough #healthtech #longevity #deeptech #engineering #biomaterials #venturecapital #defensetech #futuretech Support the show

    1h 2m

  5. 4D AGO

    Building “Off-the-Shelf” Regenerative Cell Therapies: The Next Biotech Revolution | Brian Culley - CEO, Lineage Cell Therapeutics

    Send us Fan Mail Today’s conversation sits at the intersection of one of the most ambitious - and most challenging - frontiers in modern medicine: regenerative cell therapy. For decades, the vision has been incredibly compelling - replace damaged or dying cells with healthy ones, and you could potentially restore function in diseases like macular degeneration, spinal cord injury, hearing loss, and even Type 1 diabetes. But while the science has advanced, the field has consistently run into a different kind of barrier: how do you actually manufacture living cells as consistent, scalable, affordable therapies? That’s not just a biology problem - it’s an engineering, manufacturing, and business problem. And it’s one that today’s guest has spent his entire career navigating. Brian Culley brings more than three decades of experience across the life sciences industry, spanning drug development, business development, and executive leadership. From early work in neuropharmacology at Neurocrine Biosciences, to technology transfer at University of California, San Diego, to building and leading public biotech companies like Mast Therapeutics, he’s seen the industry from nearly every angle - science, capital markets, partnerships, and operations. Today, as CEO of Lineage Cell Therapeutics ( https://lineagecell.com/ ), Brian is applying that full spectrum of experience to one of the hardest problems in medicine: how to turn the promise of regenerative cell therapy into something that can actually reach patients at scale. Under his leadership, Lineage has taken a manufacturing-first approach - building an integrated platform designed to deliver high-quality, ‘off-the-shelf’ cell therapies - and in the process has secured major partnerships with companies like Genentech and William Demant. Today, we’re going to explore not just the promise of cell therapy - but what it really takes to make it real. #CellTherapy #RegenerativeMedicine #Biotech #StemCells #Longevity #FutureOfMedicine #HealthcareInnovation #Biotechnology #GeneTherapy #MedicalBreakthrough #DrugDevelopment #PrecisionMedicine #LifeSciences #Pharma #BiotechCEO #StartupBiotech #Innovation #SciencePodcast #Healthcare #AgingResearch #VisionRestoration #HearingLoss #SpinalCordInjury #Type1Diabetes #Genentech #LineageCellTherapeutics Support the show

    46 min

  6. 4D AGO

    Non-Pharmacological Cognitive Health: The StrongerMemory Approach | Rob Liebreich - CEO, Goodwin Living

    Send us Fan Mail Today on Progress, Potential And Possibilities, we explore a different kind of breakthrough in cognitive health - not a drug, not a device, but a simple daily practice that’s quietly transforming lives. Our guest is Rob Liebreich, President and CEO of Goodwin Living ( https://goodwinliving.org/ ), an organization serving thousands of older adults across the Washington, D.C. region.  Rob has spent more than two decades at the forefront of senior living and aging services - leading large-scale communities, building platforms to improve how families navigate care decisions, and working to fundamentally shift the narrative around aging from one of decline to one of purpose and possibility. But this story isn’t just professional - it’s deeply personal. When Rob’s mother began experiencing cognitive decline, he refused to accept that deterioration was inevitable. Drawing on both his industry experience and a willingness to experiment, he developed a simple daily regimen - reading aloud, handwriting, and doing math - that helped her regain engagement, confidence, and independence. What began as a personal intervention evolved into StrongerMemory ( https://strongermemory.org/ ), a free, research-backed program now used by more than 60,000 seniors nationwide. Supported by emerging research from George Mason University, StrongerMemory is challenging conventional assumptions about what’s possible in cognitive aging - and who gets access to meaningful care. At a time when memory care can cost thousands of dollars per month and pharmaceutical solutions remain limited, Rob’s work raises a powerful question: What if one of the most effective tools for brain health isn’t something you buy - but something you do, every day? #CognitiveDecline #Alzheimers #DementiaCare #BrainHealth #Neuroplasticity #AgingWell #Longevity #MemoryCare #SeniorLiving #HealthcareInnovation #PreventativeHealth #NonPharmacological #BrainTraining #MentalFitness #Caregiving #AgingPopulation #DigitalHealth #Healthspan #PodcastClips #FutureOfHealthcare #Wellness #CognitiveHealth #BrainExercises #StrongerMemory #Neuroscience #LongevityScience #HealthyAging #PublicHealth Support the show

    45 min

  7. APR 22

    The Architecture of a Drug Empire - and the Systems It Forced the World to Build | Carlos Lehder

    Send us Fan Mail Today’s conversation is part of a new series we’re launching — ‘Past Forward: Lessons for the Next Century.’  In this series, we examine pivotal moments, systems, and individuals from the past - not to relive them, but to better understand how they continue to shape the world we are building.  Because many of the defining forces of our time - globalized networks, technological escalation, public health crises, and the evolution of law enforcement - did not emerge in isolation. They evolved from earlier systems, earlier decisions, and earlier actors operating under very different constraints. Today’s episode is titled: ‘The Architecture of a Drug Empire — and the Systems It Forced the World to Build.’ Carlos Lehder is one of the central figures in the rise of the Medellín Cartel, and someone who played a key role in developing the logistics and infrastructure that helped transform the global cocaine trade. After decades of imprisonment, he has recently published a firsthand account of that era in his book, Life and Death of the Medellín Cartel ( https://www.amazon.com/DEATH-MEDELL%C3%8DN-CARTEL-CARLOS-LEHDER/dp/B0FDL8D66M/ ) a narrative that traces his journey from early criminal activity to the creation and evolution of one of the most consequential criminal networks in modern history. This conversation is not about glamorizing crime or revisiting mythology. It is about understanding systems - how they scale, how they collide with institutions, and how their consequences ripple across decades. Across this discussion, we explore themes that connect directly to many conversations we’ve had on this show - from the evolution of global law enforcement and emerging technologies, to drug policy, harm reduction, incarceration, and even healthcare behind bars. And ultimately, the goal is simple: to extract lessons. Lessons about innovation and unintended consequences. Lessons about policy and adaptation. And lessons that may help us better understand - and perhaps better navigate - the systems we are building for the future. #PastForward #ProgressPotentialPossibilities #CarlosLehder #MedellinCartel #PabloEscobar #DrugPolicy #WarOnDrugs #TrueCrime #Geopolitics #CriminalJustice #LawEnforcement #DEA #HistoryMatters #SystemsThinking #GlobalSecurity #OrganizedCrime #Innovation #PublicHealth #HarmReduction #FutureOfPolicing #AIandCrime #DrugEpidemic #ColdWarHistory #TransnationalCrime #Podcast Support the show

    1h 13m

  8. APR 9

    The Blood Test That Could Detect Alzheimer’s Years Before Symptoms | Mike Banville - CEO, ALZpath

    Send us Fan Mail What if a simple blood test could detect Alzheimer’s years—maybe even decades—before symptoms ever appear? Mike Banville is the Chief Executive Officer of ALZpath ( https://alzpath.bio/ ), a company at the forefront of transforming how Alzheimer’s disease is detected and monitored through cutting-edge blood-based diagnostics. Mike is a seasoned global executive with a track record of scaling businesses, driving operational transformation, and executing strategic growth through both organic expansion and acquisitions. Prior to ALZpath, he served as CEO of SSB - doubling revenue and shifting the business to a predominantly recurring revenue model. Earlier in his career, Mike spent over two decades at IHS Markit, where he held multiple senior leadership roles across strategy, sales, marketing, and global operations. There, he helped scale the Telecommunications, Media, and Technology division through acquisitions and product integration, while also leading global offshoring strategy and climate-focused market development initiatives. Mike has also led and turned around companies in digital health and athlete development, bringing a consistent focus on data, analytics, and scalable platforms. Now at ALZpath, Mike is applying that same operational and strategic expertise to one of the most urgent challenges in medicine - enabling earlier, more accessible detection of Alzheimer’s disease through innovative biomarker technologies, like pTau217, helping accelerate research, improve clinical care, and ultimately impact millions of patients worldwide. #Alzheimers #AlzheimersDisease #Dementia #BrainHealth #Longevity #Biotech #HealthcareInnovation #Diagnostics #BloodTest #EarlyDetection #Neuroscience #Neurodegeneration #PrecisionMedicine #FutureOfMedicine #MedTech #Biomarkers #TauProtein #pTau217 #StartupCEO #BiotechCEO #HealthcarePodcast #MedicalBreakthrough #AgingResearch #CognitiveHealth #LifeSciences Support the show

    35 min
See All (825)

Ratings & Reviews

5
out of 5
6 Ratings

About

Interviews and Discussions With Fascinating People Who are Creating A Better Tomorrow For All Of Us - Host - Ira S. Pastor

Information

You Might Also Like